Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira, Inc.

http://www.hospira.com

Latest From Hospira, Inc.

News We’re Watching: Premom Data Privacy Settlement, Labcorp Owes $372m For Patent Violations, Elixir Stent Trial Success

This week, the DC Attorney General announced a settlement with ovulation-tracking app Premom; a novel scoliosis treatment won FDA approval; research showed Fractyl Health’s Rejuva delivery system can deliver gene therapy directly to the pancreas; and BearCare recalled a thermometer over burn risks.

Commercial Regulation

SCARDA: Japan’s Big Hope To Change Its Vaccine R&D Ecosystem

Japan's SCARDA is building networks with academia and industry to support new vaccine development, while offering support through funding and knowledge. But is that enough to overcome the shortcomings highlighted by the pandemic?

Japan Research & Development

USPTO Has Not Seen ‘Deluge’ Of Inconsistent Statements From Applicants

Agency did not intend to ‘strong-arm or threaten’ anyone in its duty to disclose notice, patent office legal advisors say. Applicants should assess whether information required by FDA on new method of manufacturing or different formulation impacts patentability.

Intellectual Property Biosimilars

Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent

Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.

Intellectual Property Legal Issues
See All

Company Information

  • Other Names / Subsidiaries
    • Javelin Pharmaceuticals, Inc.
    • Mayne Pharma Limited
UsernamePublicRestriction

Register